Yann Vano

5.7k total citations · 2 hit papers
83 papers, 2.4k citations indexed

About

Yann Vano is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yann Vano has authored 83 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 51 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Yann Vano's work include Renal cell carcinoma treatment (53 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Renal and related cancers (22 papers). Yann Vano is often cited by papers focused on Renal cell carcinoma treatment (53 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Renal and related cancers (22 papers). Yann Vano collaborates with scholars based in France, Belgium and United States. Yann Vano's co-authors include Wolf H. Fridman, Stéphane Oudard, Catherine Sautès‐Fridman, Nicolás A. Giraldo, Étienne Becht, Florent Petitprez, Xavier Cathelineau, Pierre Validire, Alexandre Ingels and Rafael Sanchez‐Salas and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Yann Vano

77 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The clinical role of the TME in solid cancer

2018 487 citations Nicolás A. Giraldo, Yann Vano et al. profile →
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

2015 356 citations Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Yann Vano

Since Specialization

Citations

This map shows the geographic impact of Yann Vano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Vano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Vano more than expected).

Fields of papers citing papers by Yann Vano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Vano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Vano. The network helps show where Yann Vano may publish in the future.

Co-authorship network of co-authors of Yann Vano

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Vano. A scholar is included among the top collaborators of Yann Vano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Vano. Yann Vano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157) 2024 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), (unknown), Laurence Albigès, G. Pignot, Gwénaëlle Gravis, P. Bigot, Nathalie Baize, Alexandre Ingels, Charlotte Joly, François Audenet, Yann Vano, (unknown), (unknown), Philippe Barthélémy, Damien Ambrosetti, (unknown), Mokrane Yacoub, (unknown), Jean‐Christophe Bernhard	0
2	Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas 2023 ·The Oncologist ·Omar Alhalabi, (unknown), Sylvie Négrier, Yann Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W. Hahn, Mehmet Asım Bilen, Pavlos Msaouel, Toni K. Choueiri, Srinivas R. Viswanathan, Kanishka Sircar, Laurence Albigès, Gabriel G. Malouf, Nizar M. Tannir	13
3	Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies 2023 ·Bulletin du Cancer ·(unknown), Yves Allory, Édouard Auclin, Claire Gervais, (unknown), (unknown), Arnaud Méjean, François Audenet, Yann Vano, Stéphane Oudard, Constance Thibault	0
4	184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study 2023 ·Immuno-Oncology Technology ·(unknown), Marie Naigeon, Ronan Flippot, Cécile Dalban, Aude Desnoyer, Nathalie Rioux‐Leclercq, Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, Benoit Beuselinck, Salem Chouaı̈b, (unknown), Florence Tantot, (unknown), (unknown), Laurence Albigès	1
5	MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights 2022 ·International Journal of Molecular Sciences ·Audrey Simonaggio, Damien Ambrosetti, Virginie Verkarre, (unknown), Stéphane Oudard, Yann Vano	19
6	Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies 2022 ·Cancers ·(unknown), (unknown), Yann Vano, Stéphane Oudard, Dominique Helley, Laëtitia Mauge	22
7	Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments 2021 ·Cancers ·Adrien Procureur, Audrey Simonaggio, Jean‐Emmanuel Bibault, Stéphane Oudard, Yann Vano	45
8	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) 2021 ·Cancers ·Audrey Simonaggio, Nicolas Epaillard, (unknown), Marco Moreira, Stéphane Oudard, Yann Vano	45
9	LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study 2021 ·Annals of Oncology ·Thomas Powles, (unknown), (unknown), Andrey Semenov, Els Everaert, (unknown), Víctor Moreno, Begoña P. Valderrama, Yann Vano, (unknown), Yohann Loriot, Taek Won Kang, (unknown), Anne O’Hagan, Maryam Hosseini, Spyros Triantos, Harleen Chhabra, (unknown), Arlene O. Siefker‐Radtke	12
10	Nouvelles AMMs : association nivolumab et cabozantinib en première ligne du carcinome rénal à cellules claires avancé 2021 ·Bulletin du Cancer ·(unknown), Yann Vano	1
11	MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features 2020 ·Modern Pathology ·Thomas Denize, (unknown), Mathilde Sibony, Hélène Blons, Marc‐Olivier Timsit, (unknown), (unknown), Chloé Broudin, (unknown), Thierry Jo Molina, Yann Vano, (unknown), Richard J. Kahnoski, Arnaud Méjean, Anne‐Paule Gimenez‐Roqueplo, Nelly Burnichon, Virginie Verkarre	18
12	Cabazitaxel Schedules in Metastatic Castration-Resistant Prostate Cancer: A Review 2020 ·Future Oncology ·(unknown), Édouard Auclin, Adrien Procureur, (unknown), Audrey Simonaggio, Nicolas Delanoy, Yann Vano, Constance Thibault, Stéphane Oudard	6
13	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer 2020 ·Bulletin du Cancer ·Nicolas Epaillard, Audrey Simonaggio, Réza Elaidi, (unknown), (unknown), Constance Thibault, Cheng‐Ming Sun, Marco Moreira, Stéphane Oudard, Yann Vano	35
14	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma 2019 ·European Journal of Cancer ·(unknown), Édouard Auclin, Philippe Barthélémy, Petri Bono, Pirkko Kellokumpu‐Lehtinen, Marine Gross‐Goupil, Guillermo de Velasco, Thomas Powles, Guillaume Mouillet, Yann Vano, Gwénaëlle Gravis, Loı̈c Mourey, Franck Priou, Frédéric Rolland, Bernard Escudier, Laurence Albigès	95
15	Immunothérapie des cancers du rein 2018 ·Bulletin du Cancer ·Yann Vano, Audrey Simonaggio, Constance Thibault, Stéphane Oudard	0
16	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma 2017 ·Clinical Cancer Research ·Nicolás A. Giraldo, Étienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez‐Salas, Alexandre Ingels, Stéphane Oudard, Audrey Moatti, Bénédicte Buttard, Sarah Bourass, Claire Germain, Xavier Cathelineau, Wolf H. Fridman, Catherine Sautès‐Fridman	263
17	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies 2017 ·Cancer Immunology Immunotherapy ·Florent Petitprez, Yann Vano, Étienne Becht, Nicolás A. Giraldo, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman	88
18	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges 2017 ·PubMed ·Laure Fournier, Alexandre Bellucci, Yann Vano, (unknown), Constance Thibault, Réza Elaidi, Stéphane Oudard, C.A. Cuénod	5
19	Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases 2016 ·Annals of Oncology ·Réza Elaidi, Yann Vano, Nicolas Aide, Laure Fournier, Désirèe Deandreis, Florence Tenenbaum, Rachida Lebtahi, (unknown), Laurence Albigès, Bernard Escudier, Florence Joly, J. Alexandre, Michela Bernardini, Stéphanie Baron, Julia Arfi‐Rouche, Cory V. Noel, (unknown), John O’Quigley, Jacques Médioni, Stéphane Oudard	36
20	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer breakdown → 2015 ·Clinical Cancer Research ·Nicolás A. Giraldo, Étienne Becht, Franck Pagès, Georgios Skliris, Virginie Verkarre, Yann Vano, Arnaud Méjean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario, Audrey Lupo, Marco Alifano, Diane Damotte, Aurélie Cazes, Frédéric Triebel, Gordon J. Freeman, Marie‐Caroline Dieu‐Nosjean, Stéphane Oudard, Wolf H. Fridman, Catherine Sautès‐Fridman	356

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact